<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33028902</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Wnt antagonist FRZB is a muscle biomarker of denervation atrophy in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>16679</StartPage><MedlinePgn>16679</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16679</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-73845-z</ELocationID><Abstract><AbstractText>Skeletal muscle and the neuromuscular junction are the earliest sites to manifest pathological changes in amyotrophic lateral sclerosis (ALS). Based on prior studies, we have identified a molecular signature in muscle that develops early in ALS and parallels disease progression. This signature represents an intersection of signaling pathways including Smads, TGF-&#x3b2;, and vitamin D. Here, we show that the Wnt antagonist, Frizzled Related Protein (FRZB), was increased in ALS muscle samples and to a variable extent other denervating disease but only minimally in acquired myopathies. In the SOD1<sup>G93A</sup> mouse, FRZB was upregulated in the early stages of disease (between 40 and 60&#xa0;days) until end-stage. By immunohistochemistry, FRZB was predominantly localized to endomysial connective tissue and to a lesser extent muscle membrane. There was a significant increase in immunoreactivity surrounding atrophied myofibers. Because FRZB is a Wnt antagonist, we assessed &#x3b2;-catenin, the canonical transducer of Wnt signaling, and found increased levels mainly at the muscle membrane. In summary, we show that FRZB is part of a molecular signature of muscle denervation that may reflect disease progression in ALS. Our findings open up avenues for future investigation as to what roles FRZB and Wnt signaling might be playing in muscle denervation/reinnervation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Thaddaeus</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294-0017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazamel</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294-0017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thoenes</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294-0017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294-0017, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294-0017, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0001-9391-7464</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294-0017, USA. phking@uabmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. phking@uabmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA. phking@uabmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS092651</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS111275</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092651</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BX001148</GrantID><Acronym>VA</Acronym><Agency>VA</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX004419</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX001148</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106866">WD repeat containing planar cell polarity effector</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009121" MajorTopicYN="Y">Muscle Denervation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33028902</ArticleId><ArticleId IdType="pmc">PMC7541525</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-73845-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-73845-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verber NS, et al. Biomarkers in motor neuron disease: A state of the art review. Front. Neurol. 2019;10:291. doi: 10.3389/fneur.2019.00291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, et al. Prevalence of amyotrophic lateral sclerosis&#x2014;United States, 2015. Morb. Mortal. Wkly. Rep. 2018;67:1285&#x2013;1289. doi: 10.15585/mmwr.mm6746a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6746a1</ArticleId><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG. Biological markers in amyotrophic lateral sclerosis: Help or hindrance? J. Neurol. 1999;246:13&#x2013;15. doi: 10.1007/bf03161084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf03161084</ArticleId><ArticleId IdType="pubmed">10631655</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve. 2016;53:169&#x2013;182. doi: 10.1002/mus.24979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24979</ArticleId><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Loeffler JP. Neuromuscular junction destruction during amyotrophic lateral sclerosis: Insights from transgenic models. Curr. Opin. Pharmacol. 2009;9:341&#x2013;346. doi: 10.1016/j.coph.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2009.03.007</ArticleId><ArticleId IdType="pubmed">19386549</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: Molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis. Neurobiol. Dis. 2018;114:85&#x2013;94. doi: 10.1016/j.nbd.2018.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.02.009</ArticleId><ArticleId IdType="pmc">PMC5891369</ArticleId><ArticleId IdType="pubmed">29486297</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. Smads as muscle biomarkers in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2014;1:778&#x2013;787. doi: 10.1002/acn3.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.117</ArticleId><ArticleId IdType="pmc">PMC4241805</ArticleId><ArticleId IdType="pubmed">25493269</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. The vitamin D activator CYP27B1 is upregulated in muscle fibers in denervating disease and can track progression in amyotrophic lateral sclerosis. J. Steroid Biochem. Mol. Biol. 2020;200:105650. doi: 10.1016/j.jsbmb.2020.105650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2020.105650</ArticleId><ArticleId IdType="pmc">PMC7274892</ArticleId><ArticleId IdType="pubmed">32142934</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. Transforming growth factor beta (TGF-beta) is a muscle biomarker of disease progression in ALS and correlates with smad expression. PLoS ONE. 2015;10:e0138425. doi: 10.1371/journal.pone.0138425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138425</ArticleId><ArticleId IdType="pmc">PMC4574401</ArticleId><ArticleId IdType="pubmed">26375954</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns L, Bouwmeester T, Kim SH, Piccolo S, De Robertis EM. Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell. 1997;88:747&#x2013;756. doi: 10.1016/s0092-8674(00)81921-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)81921-2</ArticleId><ArticleId IdType="pmc">PMC3061830</ArticleId><ArticleId IdType="pubmed">9118218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Krinks M, Lin K, Luyten FP, Moos M. Frzb, a secreted protein expressed in the spemann organizer, binds and inhibits Wnt-8. Cell. 1997;88:757&#x2013;766. doi: 10.1016/S0092-8674(00)81922-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81922-4</ArticleId><ArticleId IdType="pubmed">9118219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazamel M, et al. Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population. Amyotroph. Lateral Scler. Frontotemp. Degener. 2013;14:334&#x2013;337. doi: 10.3109/21678421.2013.770030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.770030</ArticleId><ArticleId IdType="pmc">PMC3732496</ArticleId><ArticleId IdType="pubmed">23458155</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 2015;69:5&#x2013;21. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005;236:1&#x2013;7. doi: 10.1016/j.jns.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce NC, Oskarsson B, Jin L-W. Muscle biopsy evaluation in neuromuscular disorders. Phys. Med. Rehabil. Clin. N. Am. 2012;23:609&#x2013;631. doi: 10.1016/j.pmr.2012.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmr.2012.06.006</ArticleId><ArticleId IdType="pmc">PMC4590778</ArticleId><ArticleId IdType="pubmed">22938878</ArticleId></ArticleIdList></Reference><Reference><Citation>Borello U, et al. Transplacental delivery of the Wnt antagonist Frzb1 inhibits development of caudal paraxial mesoderm and skeletal myogenesis in mouse embryos. Development. 1999;126:4247&#x2013;4255.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lories RJ, et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum. 2007;56:4095&#x2013;4103. doi: 10.1002/art.23137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23137</ArticleId><ArticleId IdType="pubmed">18050203</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, et al. Identification of genes related to growth and lipid deposition from transcriptome profiles of pig muscle tissue. PLoS ONE. 2015;10:e0141138. doi: 10.1371/journal.pone.0141138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141138</ArticleId><ArticleId IdType="pmc">PMC4624711</ArticleId><ArticleId IdType="pubmed">26505482</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang B, Moos M, Vukicevic S, Luyten FP. Primary structure and tissue distribution of FRZB, a novel protein related to drosophila frizzled, suggest a role in skeletal morphogenesis. J. Biol. Chem. 1996;271:26131&#x2013;26137. doi: 10.1074/jbc.271.42.26131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.42.26131</ArticleId><ArticleId IdType="pubmed">8824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: The bone and joint health dilemma. Nat. Rev. Rheumatol. 2013;9:328&#x2013;339. doi: 10.1038/nrrheum.2013.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2013.25</ArticleId><ArticleId IdType="pmc">PMC4830431</ArticleId><ArticleId IdType="pubmed">23459013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: New functions of secreted Frizzled-related proteins in development and disease. J. Cell Sci. 2008;121:737&#x2013;746. doi: 10.1242/jcs.026096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.026096</ArticleId><ArticleId IdType="pubmed">18322270</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz A, et al. Gene expression profiling in limb-girdle muscular dystrophy 2A. PLoS ONE. 2008;3:e3750. doi: 10.1371/journal.pone.0003750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003750</ArticleId><ArticleId IdType="pmc">PMC2582180</ArticleId><ArticleId IdType="pubmed">19015733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich CA, et al. Olfactory ensheathing cells abutting the embryonic olfactory bulb express Frzb, whose deletion disrupts olfactory axon targeting. Glia. 2018;66:2617&#x2013;2631. doi: 10.1002/glia.23515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23515</ArticleId><ArticleId IdType="pmc">PMC6517278</ArticleId><ArticleId IdType="pubmed">30256452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovolenta P, Rodriguez J, Esteve P. Frizzled/RYK mediated signalling in axon guidance. Development. 2006;133:4399&#x2013;4408. doi: 10.1242/dev.02592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.02592</ArticleId><ArticleId IdType="pubmed">17035295</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau &#xc9;, Di Polo A, Vande Velde C, Robitaille R. Dynamic neuromuscular remodeling precedes motor-unit loss in a mouse model of ALS. eLife. 2018 doi: 10.7554/eLife.41973.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.41973</ArticleId><ArticleId IdType="pmc">PMC6234026</ArticleId><ArticleId IdType="pubmed">30320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve. 1987;10:490&#x2013;502. doi: 10.1002/mus.880100603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880100603</ArticleId><ArticleId IdType="pubmed">3306367</ArticleId></ArticleIdList></Reference><Reference><Citation>von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA. Wnt signaling in myogenesis. Trends Cell Biol. 2012;22:602&#x2013;609. doi: 10.1016/j.tcb.2012.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2012.07.008</ArticleId><ArticleId IdType="pmc">PMC3479319</ArticleId><ArticleId IdType="pubmed">22944199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisternas P, Henriquez JP, Brandan E, Inestrosa NC. Wnt signaling in skeletal muscle dynamics: Myogenesis, neuromuscular synapse and fibrosis. Mol. Neurobiol. 2014;49:574&#x2013;589. doi: 10.1007/s12035-013-8540-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8540-5</ArticleId><ArticleId IdType="pubmed">24014138</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X-M, et al. Retrograde regulation of motoneuron differentiation by muscle &#x3b2;-catenin. Nat. Neurosci. 2008;11:262&#x2013;268. doi: 10.1038/nn2053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2053</ArticleId><ArticleId IdType="pubmed">18278041</ArticleId></ArticleIdList></Reference><Reference><Citation>Koles K, Budnik V. Wnt signaling in neuromuscular junction development. Cold Spring Harbor Persp. Biol. 2012 doi: 10.1101/cshperspect.a008045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a008045</ArticleId><ArticleId IdType="pmc">PMC3367558</ArticleId><ArticleId IdType="pubmed">22510459</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Beta-catenin regulates acetylcholine receptor clustering in muscle cells through interaction with rapsyn. J. Neurosci. 2007;27:3968&#x2013;3973. doi: 10.1523/jneurosci.4691-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.4691-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672526</ArticleId><ArticleId IdType="pubmed">17428970</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoon LK, Harandi VM, Br&#xe4;nnstr&#xf6;m T, Andersen PM, Liu J-X. Wnt and extraocular muscle sparing in amyotrophic lateral sclerosis. Investig. Ophthalmol. Vis. Sci. 2014;55:5482&#x2013;5496. doi: 10.1167/iovs.14-14886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-14886</ArticleId><ArticleId IdType="pmc">PMC4580151</ArticleId><ArticleId IdType="pubmed">25125606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez D, et al. ALS skeletal muscle shows enhanced TGF-&#x3b2; signaling, fibrosis and induction of fibro/adipogenic progenitor markers. PLoS ONE. 2017;12:e0177649. doi: 10.1371/journal.pone.0177649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177649</ArticleId><ArticleId IdType="pmc">PMC5433732</ArticleId><ArticleId IdType="pubmed">28520806</ArticleId></ArticleIdList></Reference><Reference><Citation>Dao DY, Yang X, Chen D, Zuscik M, O'Keefe RJ. Axin1 and Axin2 are regulated by TGF- and mediate cross-talk between TGF- and Wnt signaling pathways. Ann. N. Y. Acad. Sci. 2007;1116:82&#x2013;99. doi: 10.1196/annals.1402.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1402.082</ArticleId><ArticleId IdType="pmc">PMC2647987</ArticleId><ArticleId IdType="pubmed">18083923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart TM, et al. Dysregulation of ubiquitin homeostasis and &#x3b2;-catenin signaling promote spinal muscular atrophy. J. Clin. Investig. 2014;124:1821&#x2013;1834. doi: 10.1172/JCI71318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI71318</ArticleId><ArticleId IdType="pmc">PMC3973095</ArticleId><ArticleId IdType="pubmed">24590288</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S, et al. Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol. Comp. 2014;2:165. doi: 10.1186/s40478-014-0165-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0165-z</ArticleId><ArticleId IdType="pmc">PMC4297389</ArticleId><ArticleId IdType="pubmed">25510661</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, et al. Wnt signaling is altered by spinal cord neuronal dysfunction in amyotrophic lateral sclerosis transgenic mice. Neurochem. Res. 2013;38:1904&#x2013;1913. doi: 10.1007/s11064-013-1096-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-013-1096-y</ArticleId><ArticleId IdType="pmc">PMC4170800</ArticleId><ArticleId IdType="pubmed">23784673</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Fern&#xe1;ndez C, Gonzalez P, Andres-Benito P, Ferrer I, Rodr&#xed;guez FJ. Wnt signaling alterations in the human spinal cord of amyotrophic lateral sclerosis cases: Spotlight on Fz2 and Wnt5a. Mol. Neurobiol. 2019;56:6777&#x2013;6791. doi: 10.1007/s12035-019-1547-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1547-9</ArticleId><ArticleId IdType="pubmed">30924074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Fernandez C, et al. New insights into Wnt signaling alterations in amyotrophic lateral sclerosis: A potential therapeutic target? Neural Regener. Res. 2020;15:1580&#x2013;1589. doi: 10.4103/1673-5374.276320.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.276320</ArticleId><ArticleId IdType="pmc">PMC7437582</ArticleId><ArticleId IdType="pubmed">32209757</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubach-Powell, J. Quantitative determination of muscle fiber diameter (minimal Feret&#x2019;s diameter) and percentage of centralized nuclei. (2014).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>